MX352328B - Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. - Google Patents

Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Info

Publication number
MX352328B
MX352328B MX2015003139A MX2015003139A MX352328B MX 352328 B MX352328 B MX 352328B MX 2015003139 A MX2015003139 A MX 2015003139A MX 2015003139 A MX2015003139 A MX 2015003139A MX 352328 B MX352328 B MX 352328B
Authority
MX
Mexico
Prior art keywords
treating
methods
deficiency
testoterone
same
Prior art date
Application number
MX2015003139A
Other languages
English (en)
Inventor
E Dudley Robert
P Constantinides Panayiotis
Original Assignee
Clarus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarus Therapeutics Inc filed Critical Clarus Therapeutics Inc
Publication of MX352328B publication Critical patent/MX352328B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporciona una formulación farmacéutica de undecanoato de testosterona. También se proporcionan métodos para tratar una deficiencia de testosterona o sus síntomas con las formulaciones novedosas.
MX2015003139A 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. MX352328B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/030788 WO2011129812A1 (en) 2010-04-12 2010-04-12 Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same

Publications (1)

Publication Number Publication Date
MX352328B true MX352328B (es) 2017-11-21

Family

ID=43074118

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003139A MX352328B (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Country Status (17)

Country Link
EP (2) EP2803350B1 (es)
JP (1) JP5992397B2 (es)
KR (2) KR101460871B1 (es)
CN (1) CN102883710B (es)
AU (1) AU2010351080B2 (es)
BR (1) BR112012025961B1 (es)
CA (1) CA2795908C (es)
DK (1) DK2558073T3 (es)
ES (1) ES2525520T3 (es)
HK (1) HK1180593A1 (es)
IL (1) IL222315A (es)
MX (2) MX352328B (es)
NZ (1) NZ602821A (es)
RU (1) RU2012142997A (es)
SG (1) SG184540A1 (es)
WO (1) WO2011129812A1 (es)
ZA (1) ZA201207517B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR20080009201A (ko) 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2014096139A1 (en) 2012-12-20 2014-06-26 Solural Pharma ApS Solid oral dosage form of testosterone derivative
WO2014145518A2 (en) * 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
EP4382165A2 (en) 2013-10-07 2024-06-12 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
US9925200B2 (en) 2014-06-17 2018-03-27 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
MX2016016173A (es) 2014-06-19 2017-03-28 Solural Pharma ApS Forma de dosis oral solida de compuestos lipofilicos.
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CA2958696C (en) 2014-08-28 2022-09-06 Board Of Regents, The University Of Texas System Formulations of testosterone and methods of treatment therewith
WO2016049382A1 (en) * 2014-09-24 2016-03-31 Lipocine Inc. Compositions and their use in oral dosing regimens
WO2016205423A2 (en) * 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US20180333423A1 (en) * 2017-05-18 2018-11-22 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
CN108524485A (zh) * 2018-02-24 2018-09-14 中山大学 一种猴睾酮缺乏模型的建立方法
WO2020132163A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
JP7144346B2 (ja) 2019-03-20 2022-09-29 日立Geニュークリア・エナジー株式会社 遠隔測定システム、および、遠隔測定方法
US11564933B2 (en) * 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
WO2020210501A1 (en) * 2019-04-12 2020-10-15 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents
US20220265678A1 (en) * 2019-10-30 2022-08-25 Marius Pharmaceuticals Llc Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
MXPA01009919A (es) * 1999-04-01 2002-04-24 Akzo Nobel Nv Formulacion comprendiendo undecanoato de testosterona y aceite de ricino.
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
CA2575906C (en) * 2004-08-04 2014-04-15 Camurus Ab Compositions forming non-lamellar dispersions
KR20080009201A (ko) * 2005-04-15 2008-01-25 클라루스 쎄러퓨틱스, 아이엔씨. 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
CN101217963A (zh) * 2005-04-15 2008-07-09 克劳拉斯医疗有限公司 疏水性药物给药系统及含有疏水性药物的组合物
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions

Also Published As

Publication number Publication date
IL222315A (en) 2017-07-31
EP2803350B1 (en) 2017-09-20
CN102883710B (zh) 2014-09-10
SG184540A1 (en) 2012-11-29
DK2558073T3 (en) 2014-12-08
AU2010351080A1 (en) 2012-11-01
ES2525520T3 (es) 2014-12-26
KR101607034B1 (ko) 2016-03-28
ZA201207517B (en) 2013-06-26
BR112012025961B1 (pt) 2021-06-15
JP2013523880A (ja) 2013-06-17
EP2558073B1 (en) 2014-09-10
JP5992397B2 (ja) 2016-09-14
MX2012011952A (es) 2013-02-07
KR20130074770A (ko) 2013-07-04
AU2010351080B2 (en) 2014-08-28
KR101460871B1 (ko) 2014-11-11
KR20140012215A (ko) 2014-01-29
CA2795908C (en) 2015-10-13
RU2012142997A (ru) 2014-06-20
IL222315A0 (en) 2012-12-31
WO2011129812A1 (en) 2011-10-20
BR112012025961A2 (pt) 2018-05-15
HK1180593A1 (en) 2013-10-25
EP2558073A1 (en) 2013-02-20
NZ602821A (en) 2014-07-25
CA2795908A1 (en) 2011-10-20
CN102883710A (zh) 2013-01-16
EP2803350A1 (en) 2014-11-19

Similar Documents

Publication Publication Date Title
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
HRP20190368T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2012030993A3 (en) Skin compositions and methods of use thereof
AU333422S (en) Showerhead
SG184222A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
IL232515A0 (en) nadph 4 oxidase inhibitors and pharmaceutical preparations containing them
WO2011106297A3 (en) Compositions and methods for the diagnosis and treatment of tumor
IN2014DN07483A (es)
EP2464383A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2385769A4 (en) QUICKLY SOLUBLE VITAMIN FORMULATION AND METHOD FOR THEIR USE
UY34455A (es) Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada
EP4233915A3 (en) Modified release formulations of viloxazine
WO2008153784A3 (en) Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors
CA140996S (en) Display unit
HK1196765A1 (zh) 口服睾酮酯製劑以及包含其的治療睾酮缺乏症的方法
HK1176949A1 (zh) 新的胱天蛋白酶- 激活肽及包含所述激活肽的組合物
IL222642A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
UA59396U (ru) Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью
WO2011161465A3 (en) Composition for treatment of skin
CR20120535A (es) Formulaciones orales de éster de testosterona y métodos para el tratamiento de la deficiencia de testosterona que comprende estos
UA47350U (en) use of ethyl ester of N-[(2-oxoindolinelyden-3)-2-oxyacetyl]-aaminoacetic acids as nootropic and anxyolitic agent
AU334689S (en) Display stand and trays
AU2010903965A0 (en) Formulation and method for the treatment of timber